WB 4101

Drug Profile

WB 4101

Latest Information Update: 16 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Research Biochemicals
  • Class Anti-ischaemics; Antiarrhythmics; Antihypertensives
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Hypertension; Premature ejaculation; Reperfusion injury

Most Recent Events

  • 16 Oct 2003 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
  • 16 Oct 2003 Discontinued - Preclinical for Premature ejaculation in Taiwan (unspecified route)
  • 16 Oct 2003 Discontinued - Preclinical for Reperfusion injury in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top